Novartis has announced new clinical trial data that demonstrates the promise offered by its new inflammatory atherosclerosis therapy ACZ885.
Data from the data from the phase III CANTOS study has shown that targeting inflammation with ACZ885 can effectively reduce cardiovascular risk in people with a prior heart attack and inflammatory atherosclerosis.
“Novartis has reported new clinical data showing how the new drug ACZ885 can reduce cardiovascular risk in people with a prior heart attack and inflammatory atherosclerosis.“
Quarterly injections of ACZ885 led to a statistically significant 15 percent reduction in the risk of major adverse cardiovascular events compared to placebo, a benefit that was sustained throughout the duration of the study and was largely consistent across key pre-specified baseline subgroups.
Additionally, a review of blinded preplanned oncology safety analyses revealed a 77 percent reduction in lung cancer mortality and 67 percent reduction in lung cancer cases in patients treated with ACZ885
Vas Narasimhan, global head of drug development and chief medical officer at Novartis, said: "We look forward to submitting the CANTOS data to regulatory authorities for approval in cardiovascular and initiating additional phase III studies in lung cancer."
More than 10,000 patients were enrolled in the CANTOS study over the last six years, making it one of the largest and longest-running clinical trials in Novartis' history.
With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.See all the latest jobs in Pharmaceutical